[Featured Stock] Genome Analysis Technology Platform Company Selemix Hits Upper Limit
Genome analysis technology platform company Selemix is hitting the upper price limit.
As of 9:06 AM on the 12th, Selemix is trading at 5,200 KRW on the KOSDAQ market, up 1,200 KRW (30%) from the previous trading day.
Selemix has developed the next-generation cloning technology MSSIC and three productization technologies, conducting businesses in Target Capture kits, immune repertoire analysis solutions, and next-generation sequencing solutions.
It supplies products to major institutions in the bio industry such as hospitals, contract testing organizations, pharmaceutical companies, seed companies, and research institutes.
Hot Picks Today
"Why Is the Amount in My Account So Low?"... Why Pension Savings Subscribers Were Surprised
- As Kim Jong Un Death Rumors Spread... "It's Not Loading Again": North Korean State Media Sites Face Outages
- President Lee: "Will Work to Ensure Sabuk Incident Is Remembered as a History of Restored Justice"
- "After Sleeping Well with Strangers"... Who Is the 24-Year-Old Woman Who Won 19 Million Won?
- "I wanted her to feel my passionate love"... Wife collapses after husband's overly tight hug, diagnosed with broken ribs
It is used as an essential material to create value in a wide range of fields including diagnostics, new drug development, seed development, synthetic biology, microbiome, and academic research.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.